Strategic Shape Diagnostic
Service Line
Delivered as a service through an owned lab or facility rather than sold as a product. CLIA labs, imaging services, interpretation services. Device and diagnostics only. The Service Line shape has no biopharma analog. SL companies are valued on margins, capacity utilization, and contract structure — not on product development milestones or regulatory approvals. The acquirer set is entirely distinct from product companies.
Deal Structures
How this shape transacts
Service platform acquisition priced on EBITDA or revenue multiples with margin expansion potential
Margin-based valuation tied to capacity utilization, contract mix, and payor reimbursement rates
Lab or facility acquisition with capacity expansion thesis
Contract-based partnerships with volume guarantees and exclusivity provisions
Contradictions
Common contradictions for SL companies
Contradiction 01
Calling a service business a technology company — if the value delivery requires an owned facility and staff performing the service, it is a service business regardless of the technology used internally
Contradiction 02
Applying technology company multiples to a service business revenue base
Contradiction 03
Describing the company as scalable when capacity expansion requires new facilities, equipment, and staff
Counterparty View
What counterparties expect
Acquirers evaluate SL companies on margin profile, capacity utilization, geographic coverage, payor mix, and contract renewal rates. They apply service-business valuation frameworks — typically EBITDA multiples with adjustments for contract quality and growth trajectory. The premium available to SL companies comes from demonstrated margin stability and geographic density, not from technology differentiation.
Find out if this is your shape.
The Shape Diagnostic classifies your company into one of seven archetypes in seven minutes.
Free classification · $49 full report